Page-2 of Bharat Biotech

Covid: WHO recommends 3rd dose for immunocompromised

The World Health Organisation (WHO) has recommended for third dose of immunocompromised, following a four-day meeting of the “Strategic Advisory Group of Experts (SAGE) on Immunization”.  The final report on the matter will be issued in December. Key Points According ..

Month: 

Nasal Covid Vaccine Gets Regulatory Nod for further trials

India’s first nasal vaccine against COVID-19 has received the nod to conduct phase 2 and 3 clinical trials by the Department of Biotechnology. Key Points Nasal Covid Vaccine has been developed by Bharat Biotech. Vaccine has successfully completed Phase 1 ..

Month: 

IndRa: Cost of vaccinating India’s population above 18 years 0.36% of GDP

The India Ratings and Research (Ind-Ra) recently said the estimated cost to vaccinate all the Indians of age 18 years will be Rs 67,193 crores. This is 0.36% of the GDP of the country. Key Findings The GoI recently announced ..

Month: 

COVAXIN: Transfer of Technology from Bharat Biotech to Haffkine

The Government of India recently approved the transfer of technology from Bharat Biotech to Hafkine Institute. COVAXIN COVAXIN is one of the two drugs that is currently administered in India. It is manufactured by Bharat Biotech in collaboration with the ..

Month: 

India approved two COVID-19 vaccines for Emergency Use

The Drug Controller General of India recently announced that it has authorised two COVID-19 vaccines for restricted Emergency Use in India. What are the two COVID-19 Vaccines approved by DGCI for emergency use? COVAXIN and COVISHIELD What is COVAXIN? The ..

Month: 

COVAXIN of Bharat Biotech enters Phase III trials: Largest COVID-19 clinical trial of India

On November 16, 2020 the Bharat Biotech announced the commencement of Phase III trials of COVAXIN vaccines in India. The trials will involve 26,000 volunteers. It is to be held in partnership with the Indian Council of Medical Research. The ..

Month: